ACRX AcelRx Pharmaceuticals, Inc.

3.10
+0  (0%)
Previous Close 3.10
Open 3.15
Price To book 43.06
Market Cap 140.53M
Shares 45,333,000
Volume 178,015
Short Ratio 17.80
Av. Daily Volume 220,873

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released August 15 2016
ARX-04 (SAP302)
Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury
NDA filing announced December 13, 2016.
ARX-04 (SAP303)
Moderate-to-severe acute pain following a surgical procedure
CRL Jul 26 2014. Additional clinical trial initiated September 2016.
Zalviso
Post-operative pain following open abdominal surgery and hip or knee replacement surgery

Latest News

  1. ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
  2. AcelRx Pharmaceuticals Appoints Vincent J. Angotti Chief Executive Officer
  3. AcelRx Pharmaceuticals Presentation at JAB Burn Symposium Highlights Potential of DSUVIA™ for Use in Burn Victims with Moderate-to-Severe Acute Pain
  4. ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
  5. AcelRx Pharmaceuticals to Participate at Four Upcoming Investor Events in February
  6. AcelRx Pharmaceuticals (ACRX) in Focus: Stock Rises 5.3%
  7. ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur
  8. AcelRx Pharmaceuticals Provides Guidance on 2017 Milestones for ARX-04, now known as DSUVIA™ in the United States, for the Treatment of Moderate-to-Severe Acute Pain
  9. AcelRx Pharmaceuticals Announces DSUVIA™ as Brand Name for ARX-04 in the United States
  10. The Story of AcelRx (ACRX), an Innovator in Developing & Commercializing Therapies for the Treatment of Acute Pain
  11. Does AcelRx Pharmaceuticals Inc (ACRX) Stack Up Against Its Peers?
  12. ETFs with exposure to AcelRx Pharmaceuticals, Inc. : December 13, 2016
  13. ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  14. AcelRx Pharmaceuticals Submits New Drug Application for ARX-04 for the Treatment of Moderate-To-Severe Acute Pain
  15. AcelRx Pharmaceuticals Reports on ARX-04 Market and Landscape Presented at Analyst & Investor Event
  16. ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  17. AcelRx Pharmaceuticals Updates Agenda for Analyst & Investor Event Focusing on Innovative Therapies for Treatment of Acute Pain
  18. Edited Transcript of ACRX earnings conference call or presentation 1-Nov-16 8:30pm GMT
  19. AcelRx Pharmaceuticals Unveiling Results of ARX-04 SAP303 Study in Post-Operative Setting at the Annual ASRA Pain Medicine Meeting

SEC Filings

  1. 8-K - Current report 17618510
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 17611601
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17610630
  4. 8-K - Current report 17588678
  5. CT ORDER - Confidential treatment order 17552092
  6. 8-K - Current report 17515708
  7. 8-K - Current report 162047581
  8. 8-K - Current report 162026899
  9. 8-K - Current report 161969180
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 161965874